Can Consumers Self-Select for Appropriate Use of an Over-the-Counter Statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study

American Journal of Cardiology

Volumn 101, Issue 10, 2008, Pages 1448-1455

  Brass, Eric P ^a   Vassil, Theodore ^b   Replogle, Amy ^b   Hwang, Peggy ^b   Rusche, Steven ^b   Shiffman, Saul ^c,d   Levine, Jeffrey G ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d PINNEY ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NON PRESCRIPTION DRUG;

ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONSUMER; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG LABELING; DRUG USE; HUMAN; LIPID ANALYSIS; LIVER DISEASE; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; SELF EVALUATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CHOLESTEROL, LDL; CONSUMER PARTICIPATION; DRUG LABELING; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PUBLIC HEALTH; QUESTIONNAIRES; RISK FACTORS; SELF-EVALUATION PROGRAMS; UNITED STATES;

EID: 42749088018     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.01.020     Document Type: Article

References (22)

1. Genest J., and Pedersen T.R. Prevention of cardiovascular ischemic events: high-risk and secondary prevention. Circulation 107 (2003) 2059-2065
2. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
3. Arnett D.K., Jacobs Jr. D.R., Luepker R.V., Blackburn H., Armstrong C., and Claas S.A. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. Circulation 112 (2005) 3884-3891
4. Goff Jr. D.C., Bertoni A.G., Kramer H., Bonds D., Blumenthal R.S., Tsai M.Y., and Psaty B.M. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 113 (2006) 647-656
5. Lai L.L., Poblet M., and Bello C. Are patients with hyperlipidemia being treated?. Investigation of cholesterol treatment practices in an HMO primary care setting. South Med J 93 (2000) 283-286
6. Gemmell I., Verma A., and Harrison R.A. Should we encourage over-the-counter statins?. A population perspective for coronary heart disease prevention. Am J Cardiovasc Drugs 7 (2007) 299-302
7. Smith Jr. S.C. Bridging the treatment gap. Am J Cardiol 85 suppl (2000) 3E-7E
8. Fuster V. A new perspective on nonprescription statins: an opportunity for patient education and involvement. Am J Cardiol 100 (2007) 907-910
9. OTC statins: a bad decision for public health. Lancet 363 (2004) 1659
10. Strom B.L. Statins and over-the-counter availability. N Engl J Med 352 (2005) 1403-1405
11. Abrams J. Over-the-counter statins: a new controversy. Nat Clin Prac Cardiovasc Med 2 (2005) 174-175
12. Brass E.P. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 345 (2001) 810-816
13. Melin J.M., Struble W.E., Tipping R.W., Reynolds J.M., Vassil T.C., Levy S.J., Petrohoy T.M., Midgette P., Hemwall E.L., Levine J.G., and Irvin J.D. A Consumer Use Study of Over-The-Counter lovastatin (CUSTOM). Am J Cardiol 94 (2004) 1243-1248
14. Brass E.P. Consumer behavior in the setting of over-the-counter statin availability: lessons from the consumer use study of OTC Mevacor. Am J Cardiol 94 suppl (2004) 22F-29F
15. Brass E.P., Allen S.E., and Melin J.M. Potential impact on cardiovascular public health of over-the-counter statin availability. Am J Cardiol 97 (2006) 851-856
16. United States Food and Drug Administration. Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic & Metabolic Drugs Advisory Committee January 13-14, 2005. http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4086M1.htm Accessed October 23, 2007
17. Adult Treatment Panel III. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
18. Michos E.D., Nasir K., Braunstein J.B., Rumberger J.A., Budoff M.J., Post W.S., and Blumenthal R.S. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 184 (2006) 201-206
19. Ridker P.M., Buring J.E., Rifai N., and Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297 (2007) 611-619
20. Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., Dolor R.J., Ganiats T.G., Gomes A.S., Gornik H.L., Gracia C., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
21. Gotto Jr. A.M. Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population. Am J Cardiol 85 suppl (2000) 8E-14E
22. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622